Service Dogs Can Make a Difference in the Lives of Those with Addison’s Disease
source: pixabay.com

Service Dogs Can Make a Difference in the Lives of Those with Addison’s Disease

By Caitlin Seida from In The Cloud Copy Medical alert dogs can give their companions a newfound sense of independence and freedom. Enter Bill, a golden retriever owned by Laura…

Continue Reading Service Dogs Can Make a Difference in the Lives of Those with Addison’s Disease
The Results From This Immune Thrombocytopenia Trial are Good News for Patients
source: pixabay.com

The Results From This Immune Thrombocytopenia Trial are Good News for Patients

According to a story from ucb.com, the biopharmaceutical company UCB has recently released the final results from its phase 2 clinical trial which tested the company's investigational monoclonal antibody rozanolixizumab…

Continue Reading The Results From This Immune Thrombocytopenia Trial are Good News for Patients
Zotiraciclib, a New Treatment for Glioma, is Granted Orphan Drug Designation
Source: Pixabay.com

Zotiraciclib, a New Treatment for Glioma, is Granted Orphan Drug Designation

  The European Organization for Research and Treatment of Cancer (EORTC) has been evaluating zotiraciclib, which is a new treatment for glioma. This drug has recently been granted the Orphan…

Continue Reading Zotiraciclib, a New Treatment for Glioma, is Granted Orphan Drug Designation

At 49, She Got Her PhD to Help Her Son With Angelman. Now, She Created COMBINEDBrain To Help Many Related Rare Diseases.

As originally reported in Angelman Syndrome News, Terry Jo Bichell is a PhD researcher, former director and scientific officer of the Angelman Biomarkers and Outcomes Measures Alliance and Tennessee's ambassador…

Continue Reading At 49, She Got Her PhD to Help Her Son With Angelman. Now, She Created COMBINEDBrain To Help Many Related Rare Diseases.
FDA Committee to Hold Review for Reblozyl as a Treatment for Myelodysplastic Syndromes
source: pixabay.com

FDA Committee to Hold Review for Reblozyl as a Treatment for Myelodysplastic Syndromes

According to a story from BioPortfolio, Acceleron Pharma and the Bristol-Myers Squibb Company have announced recently that the US Food and Drug Administration (FDA) will review the supplemental Biologics License…

Continue Reading FDA Committee to Hold Review for Reblozyl as a Treatment for Myelodysplastic Syndromes